Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

MAGMAbots MAGnetic hyperthermia agents based on Magnetically Activated microroBOTS.

Coordinator
Fondazione Istituto Italiano Di Tecnologia, Italy
Runs
1 August 2026 to 31 July 2028
Status
Running
EU funding
€209k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101277686

What the project is doing

In the project's own words, from its summary on CORDIS.

The MAGMAbots project proposes the development of three innovative magnetically actuated microrobots (MAMs)—based on magnetic nanoparticles (MNP)-loaded neutrophils, probiotic bacteria, and magnetotactic bacteria—for cancer therapy through magnetic hyperthermia (MHT) and advanced imaging. The objectives are: (1) to design and characterize neu-MAGMAbot, an MAM based on neutrophils, evaluating its penetration across a 3D blood–brain barrier (BBB) model and its anticancer activity against glioblastoma; (2) to engineer pro-MAGMAbot, a probiotic-based microrobot, and test its targeting, cytotoxicity, and hyperthermia performance in colorectal cancer spheroids; and (3) to develop mag-MAGMAbot, MAMs based on magnetotactic bacteria with enhanced magnetosome-based magnetic and diagnostic properties.

The project will achieve these objectives based on a patented-driven methodology. This strategy preserves cell viability while enabling robust MNP internalization, and subsequent magnetic guidance via rotating magnetic fields, and real-time tracking through MPI/MRI. The work plan integrates advanced nanoparticle engineering, microfluidic BBB-on-chip models, 3D cancer spheroids, and multimodal imaging technologies, supported by the host group’s expertise in nanomaterials, magnetism, and biomedical applications.

Aligned with Horizon Europe’s Health Cluster and the Mission on Cancer, MAGMAbots directly addresses the challenge of developing innovative, non-invasive, and cost-effective therapeutic solutions for hard-to-treat tumours such as glioblastoma and colorectal cancer. Beyond the project’s duration, the results are expected to pave the way for scalable, patentable biohybrid microrobots, reduce healthcare costs, and reinforce European leadership in nanomedicine and biomedical innovation.

Topics

Who is involved

OrganisationCityCountryRole
Fondazione Istituto Italiano Di TecnologiaGenovaItalyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI